Get started
III

INTERVACC AB

No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals

IVACC fundamentals

Key facts

Market capitalization—
Dividend yield (indicated)—
Price to earnings Ratio (TTM)—
Basic EPS (TTM)—
Founded—
Employees (FY)—
CEO—
Website—
About

Intervacc AB engages in the development of novel veterinary vaccines. It markets veterinary vaccines through its subsidiary Nordvacc Läkemedel AB. The company was founded by Jan-Ingmar Flock, Bengt Guss, Kenneth Janzon, and Rune Bergman in 2001 and is headquartered in Stockholm, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

IVACC does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future

Financial health

Financial position and solvency of the company